Myasthenia Gravis Trial Set for CAR T CABA-201
The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis.
Source: ajmc.com
Caba 201 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Caba 201. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Caba 201 Today - Breaking & Trending Today
Cabaletta Bio Gets FDA's Nod For CABA-201 INDA For Generalized Myasthenia Gravis
Clinical-stage biotechnology company Cabaletta Bio, Inc. (CABA) Monday announced that FDA has allowed its Investigational New Drug or IND application for CABA-201 to proceed for a Phase 1/2 study in patients with generalized myasthenia gravis.
Source: rttnews.com